Benzphetamine

Summary

Benzphetamine (CHEMBL3545985) is an approved small-molecule sympathomimetic agent.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 239.35 Da · C17H21N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545985
Name	Benzphetamine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5311017
ChEBI	CHEBI:3044
Molecular formula	C17H21N
Molecular weight	239.35
InChIKey	YXKTVDFXDRQTKV-HNNXBMFYSA-N

SMILES: C[C@@H](CC1=CC=CC=C1)N(C)CC2=CC=CC=C2

IUPAC name: (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine

ChEBI definition: Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.

Pharmacological roles (ChEBI): sympathomimetic agent, dopamine uptake inhibitor, appetite depressant, adrenergic uptake inhibitor.

Also known as: Benzfetamina, Benzfetamine, benzphetamine, Benzphetamine, BENZPHETAMINE

Parent form; salt/anhydrous children: CHEMBL3544906

Patent coverage: 2,191 distinct patent families (7,691 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A2	7.44	AC50	36	nM	CHEMBL_ACT_25145594
SLC6A4	7.12	AC50	75	nM	CHEMBL_ACT_25150922
ADRA2C	6.17	AC50	680	nM	CHEMBL_ACT_25148490
OPRK1	5.71	AC50	1974	nM	CHEMBL_ACT_25129983
ADRA2B	5.55	AC50	2800	nM	CHEMBL_ACT_25144294
ADRA1A	5.16	AC50	6961	nM	CHEMBL_ACT_25138262
SLC6A3	5	AC50	9900	nM	CHEMBL_ACT_25124550

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).